Revision as of 17:08, 30 September 2013

Header

This iGEM project reaches now an end, but the seed of its idea is still growing in our minds and hopefully in yours! We dream of further and similar projects led whenever we'll have the opportunity. We found recent articles written about researches that share one or more characteristics with what we had foreseen and we have our own ideas about what could be further investigated. Let's share those plans!

The device we designed was thought as a proof of principle. It is highly modular and can hence be adapted in several ways for various applications.

Some may think that our device is too fragile and could never cross the stomach. However, we thought about the possibility, often used in pharmacology, to use pH sensitive capsules that open at the end of the stomach. It would be possible to encapsulate an entire batch of Taxi.Coli bacteria inside such capsule, releasing the Taxi.Colis upon arrival in the intestine only.

We chose to use E. Coli as chassis organism for practical reasons, but for a medical or industrial implementation, others may be preferred.

We had thought about two dream-carriers our device could be adapted for. The first would be a bacterium able to use chemotaxis to localize a given target (e.g. tumors or pathgenic microorganisms) with a safety mechanism implemented (inducible switch for apoptosis, limited number of division possible,...), preventing from any harm to the human body. This would allow targeted drug delivery at least in external body parts such as the digestive track and the lungs. We are now certain that this vision of the project is realistic, since [such bacteria have been recently used to hunt pathogens|http://www.nature.com/news/engineered-bacterium-hunts-down-pathogens-1.13727], only without nanoparticles, but through direct attack. Being able to conjugate our highly adaptable device with bacteria that show such a performance would be optimal for efficient targeted drug delivery and the opportunity to modify the sensed environment and change the delivered drug easily is a great way to reduce costs and allow wider distribution of such a device. The second carriers we thought about for the future of our device are immune cells. Indeed, conjugating the nanoparticles to our own sentinels would allow to release drug almost anywhere in the body! They would hunt pathogens as usual, but have more weapons to fight them once localized. However, this solution is more complicated to implement, since working with human cells is much trickier than engineering bacteria and immune compatibility must be taken into account.

Considering all those possible openings, we think that our dream could become true! The Taxi.Coli device, after optimisation, could be reasonably adapted for large scale production, becoming a cheaper but nonetheless very efficient and modular device. Should it be for personalised medicine, preventive device (bacteria as sentinels in our intestinal tract) or massive cancer therapy, a wide horizon is open in front of our taxi's army...

Team:EPF Lausanne/Future

From 2013.igem.org

Revision as of 17:08, 30 September 2013

Header

Wiki Links

@@ Line 11: / Line 11: @@
 We chose to use E. Coli as chassis organism for practical reasons, but for a medical or industrial implementation, others may be preferred.
-We had thought about two dream-carriers our device could be adapted for. The first would be a bacterium able to use chemotaxis to localize a given target (e.g. tumors or pathgenic microorganisms) with a safety mechanism implemented (inducible switch for apoptosis, limited number of division possible,...), preventing from any harm to the human body. This would allow targeted drug delivery at least in external body parts such as the digestive track and the lungs. We are now certain that this vision of the project is realistic, since such bacteria have been recently used to hunt pathogens (http://www.nature.com/news/engineered-bacterium-hunts-down-pathogens-1.13727), only without nanoparticles, but through direct attack. Being able to conjugate our highly adaptable device with bacteria that show such a performance would be optimal for efficient targeted drug delivery and the opportunity to modify the sensed environment and change the delivered drug easily is a great way to reduce costs and allow wider distribution of such a device.
+We had thought about two dream-carriers our device could be adapted for. The first would be a bacterium able to use chemotaxis to localize a given target (e.g. tumors or pathgenic microorganisms) with a safety mechanism implemented (inducible switch for apoptosis, limited number of division possible,...), preventing from any harm to the human body. This would allow targeted drug delivery at least in external body parts such as the digestive track and the lungs. We are now certain that this vision of the project is realistic, since [such bacteria have been recently used to hunt pathogens|http://www.nature.com/news/engineered-bacterium-hunts-down-pathogens-1.13727], only without nanoparticles, but through direct attack. Being able to conjugate our highly adaptable device with bacteria that show such a performance would be optimal for efficient targeted drug delivery and the opportunity to modify the sensed environment and change the delivered drug easily is a great way to reduce costs and allow wider distribution of such a device.
 The second carriers we thought about for the future of our device are immune cells. Indeed, conjugating the nanoparticles to our own sentinels would allow to release drug almost anywhere in the body! They would hunt pathogens as usual, but have more weapons to fight them once localized. However, this solution is more complicated to implement, since working with human cells is much trickier than engineering bacteria and immune compatibility must be taken into account.